Personally I don't read into any broker reports, it's always been about the company/hype, my personal beliefs and research when I invest. Maybe that long or short term investment. I do both. I agree our risks involving Chinese regulatory are reduced, but it's really naive to say it's a not a risk at this point. I think GS identified that well, however haven't noticed it effecting any of there client holdings as yet. That risk will be on the table until the approval is in hand ( sooner rather than later I hope) Having said that I don't think our expected "correction" on Monday/Tuesday will be anything to do with CFDA approval, and I don't see A2 as being in a "bubble", we've been quite steady with our little surges and following minor corrections.
Happy trading DYOR
Goldman sachs comment, page-22
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.81 |
Change
-0.090(1.84%) |
Mkt cap ! $3.482B | |||
| Open | High | Low | Value | Volume |
| $4.92 | $4.95 | $4.80 | $8.716M | 1.802M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10795 | $4.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.83 | 5662 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| A2M (ASX) Chart |